Canadian Agency for Drugs and Technologies in Health
Record ID 32006001112
Authors' objectives:

The aim of this study was to summarize the available information on the use of vildagliptin, (trade name Galvus, manufactured by Novartis).

Authors' recommendations: To determine vildagliptin's place in therapy, additional information on its efficacy, safety, and cost is required. More research is underway, and as of September 28, 2006, showed 11 ongoing trials with vildagliptin. Currently, the evidence with vildagliptin is limited to surrogate markers of effectiveness (e.g., A1C). Longer-term clinical research is needed to establish the clinical benefits of vildagliptin (i.e., reduction of diabetes complications, and long-term tolerance). As a result, it may not be possible to establish the clinical and cost effectiveness of vildagliptin versus other hypoglycemic agents for some time.
Authors' methods: Overview
Project Status: Completed
Year Published: 2006
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Canada
MeSH Terms
  • Adenosine Deaminase
  • Diabetes Mellitus, Type 2
  • Glycoproteins
  • Protease Inhibitors
Organisation Name: Canadian Agency for Drugs and Technologies in Health
Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
Contact Email:
Copyright: Canadian Agency for Drug and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.